Dabrafenib Plus Trametinib Deemed Promising for BRAF-Mutant High-Grade Glioma
Dabrafenib plus trametinib can produce durable responses in pediatric patients with relapsed or refractory, BRAFV600-mutant high-grade glioma, a phase 2 trial suggests.
Dabrafenib plus trametinib can produce durable responses in pediatric patients with relapsed or refractory, BRAFV600-mutant high-grade glioma, a phase 2 trial suggests.
There is some evidence to support the use of cannabis for symptom management in children with cancer, but there is a lack of evidence on the safety and efficacy of cannabinoids in this patient population, according to researchers.
Birth weight may be associated with the risk of certain pediatric cancers, a new study suggests.
Among children receiving maintenance therapy for ALL, those living in extreme poverty had a nearly 2-fold greater risk of relapse than those not living in extreme poverty.
Children who live near areas where fracking takes place appear to have an increased risk of lymphoma.
A polygenic risk score can predict the risk of second malignant neoplasms in pediatric cancer survivors who were treated with chemotherapy, according to researchers.
Young patients with lymphoma or rhabdomyosarcoma may experience changes in body composition during chemotherapy, research suggests.
The overall incidence of pediatric cancer in the United States increased from 2003 to 2019, researchers found.
Children, adolescents, and young adults with cancer may experience a psychological burden lasting years after diagnosis, a review suggests.
Oncology leaders testified before a House subcommittee about how drug shortages are hindering cancer care in the US and threatening the lives of patients.